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Abstract
Introduction: Mesenchymal stem cells (MSCs) can differentiate into various connective tissue cells. Several
techniques have been used for the clinical application of MSCs in articular cartilage repair; however, there are
many issues associated with the selection of the scaffold material, including its ability to support cell viability and
differentiation and its retention and degradation in situ. The application of MSCs via a scaffold also requires a
technically demanding surgical procedure. The aim of this study was to test the outcome of intra-articular
transplantation of mesenchymal stem cells suspended in hyaluronic acid (HA) in the knee joints of Hartley strain
guinea pigs with spontaneous osteoarthritis (OA).
Methods: Commercially available human MSCs were cultured, labeled with carboxyfluorescein diacetate
succinimidyl ester (CFDA-SE), suspended in either PBS or HA, and injected into the knee joints of 7-month-old
animals. The control animals were injected with either PBS or HA alone. The animals were sacrificed at 1, 3, and 5
weeks post transplantation, the knee joints harvested, and fluorescent microscopic analysis was performed.
Histological and immunohistochemical analysis were performed at 5 weeks post transplantation.
Results: At 5 weeks post transplantation, partial cartilage repair was noted in the HA-MSC group but not in the
other groups. Examination of CFDA-SE-labeled cells demonstrated migration, differentiation, and proliferation of
MSC in the HA-MSC group. There was strong immunostaining for type II collagen around both residual
chondrocytes and transplanted MSCs in the OA cartilage.
Conclusion: This scaffold-free and technically undemanding technique appears to result in the regeneration of
articular cartilage in the spontaneous OA animal model. Although further examination of the long-term effects of
transplantation is necessary, the findings suggest that intra-articular injection of HA-MSC mixture is potentially
beneficial for OA.
Introduction
Osteoarthritis (OA) of the knee joint is characterized
pathologically by degeneration of articular cartilage,
sclerosis of the subchondral bone, and marginal osteo-
phyte formation, and is characterized clinically by
chronic devastating pain and disability in the elderly.
OA is a major public health problem and its prevalence
is expected to increase dramatically and rapidly over the
next 20 years with an increasingly aged population [1].
Although tibial osteotomy and total knee arthroplasty
have been pursued in a large number of patients to
eliminate joint pain and improve joint function, the
majority of patients with knee OA are managed conser-
vatively with medication and/or physiotherapy. Develop-
ment of less technically demanding but effective
therapies for knee OA, such as cell transplantation with
or without scaffold enhancement, is therefore desirable.
Mesenchymal stem cells (MSCs) have the capacity to
differentiate into a variety of connective tissue cells
[2-6]. Several techniques have been used for the clinical
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application of MSCs in articular cartilage repair [7,8]. In
general, the cells are delivered into either the cartilage
or bone using a three-dimensional scaffold fixed to the
articular defect site. There are many issues associated
with the selection of the scaffold material, however,
including its ability to support cell viability and differen-
tiation and its retention and degradation in situ. More-
over, the application of MSCs via a scaffold usually
requires a technically demanding surgical procedure. On
the other hand, direct intra-articular injection of MSCs
has only been carried out in a limited experimental set-
ting [9,10]. In these animal studies, autologous MSCs -
mixed with a dilute solution of sodium hyaluronan (hya-
luronic acid (HA)) as a cell binding or cytotactic factor -
were directly injected into the knee joint of surgically
induced knee OA or focal cartilage defect in certain ani-
mal models. The procedure resulted in retardation of
the progression of destruction of the degenerative carti-
lage. Although the injection of MSCs in HA may be the
simplest approach clinically, disease progression is rapid
in these models, thus making it less amenable to thera-
peutic intervention [11]. The potential outcomes of this
method as a treatment for the slowly progressive pro-
cess of cartilage degeneration, as commonly occurs in
human OA, are still unknown.
The objective of the present study was to determine
whether intra-articular injection of MSCs suspended in
HA solution into the knee joint enhances the repair of
degenerated cartilage in an animal model of sponta-
neous OA. We used Hartley strain guinea pigs because
these animals spontaneously develop degenerative carti-
lage changes in the knee joint that mimic those of
human OA [11-13]. The disease is generally bilaterally
symmetrical on the medial tibial plateau in an area
unprotected by the meniscus, and the earliest changes
can be seen when animals are approximately 3 months
old [12,13]. This animal model is more suitable for the
evaluation of disease-modifying treatments.
Materials and methods
Experimental animals
Seven-month-old male Hartley strain guinea pigs (n =
60) weighing 928 ± 4.8 g (mean ± standard deviation)
were used. The experimental protocol met the Animal
Care Ethics Committee Guidelines for Experimental
Studies of Fukui Medical University and Institutional
Review Board Guidelines for Stem Cell Research.
Preparation of human MSCs for in vivo tracing
Human MSCs were purchased from Lonza (lot number
PT-2501; Lonza, Walkersville, MD, USA). The cells
were cultured at 37°C in a humidified atmosphere of 5%
CO2 in mesenchymal stem cell growth medium
(MSCGM™; Lonza). The medium was replaced every 3
days. Seven to 10 days after incubation, the cells reached
75% confluence in the seeded flask and were subcul-
tured. Cells from passages three to five were used for
the experiments. For in vivo tracing, the MSCs were
labeled with carboxyfluorescein diacetate succinimidyl
ester (CFDA-SE) (Vybrant CFDA SE Cell Tracer Kit (V-
12883); Molecular Probes, Eugene, OR, USA) as
described previously [14].
Intra-articular injection of MSCs
The labeled cells were carefully introduced into a new
syringe together with 2 ml HA (molecular weight 8 ×
105, Artz®; Seikagaku Kogyo, Tokyo, Japan), and the cell
suspension containing 7.0 × 106 labeled MSCs was
injected into the medial compartment of the left knee
joint of 7-month-old guinea pigs. For this purpose, an
18-gauge needle was inserted posterior to the medial
edge of the patellar ligament, through the triangle
formed by the epicondyle of the femur, the meniscal/
tibial plateau, and the notch formed by their junction.
Subtyping of animal groups and histological samples
The animals were divided into four treatment groups at
random: PBS group (n = 15), HA-injected group (n =
15), PBS + MSC group (n = 15), and HA + MSC group
(n = 15). The control groups were similar to the test
groups with respect to age and weight. In each group,
the animals were sacrificed at 1, 3, and 5 weeks post
transplantation of cells and/or carrier. The proximal
tibia was dissected out and prepared for examination.
Macroscopic examination
The surface of the distal head of the femur and the
tibial plateau were exposed. India ink (2 ml) was
injected onto the joint surface using a syringe, and 1
minute later the surfaces were washed with physiological
saline. The staining pattern of the cartilage surface was
observed macroscopically. The gross findings were clas-
sified and scored into six grades according to the assess-
ment suggested by Hayashi and colleagues [15]. The
assessment was conducted by two independent exami-
ners (HN, TM), who were blinded to each other’s find-
ings and to the treatment group assignment of the
animals. Finally, the scores evaluated by these two
examiners were averaged to obtain the overall score.
Histological and immunohistochemical examinations
The proximal tibia was harvested and fixed in 10% buf-
fered formaldehyde solution at 4°C for 48 hours. The
samples were snap frozen in liquid nitrogen and then
embedded in optimal cutting temperature compound.
The frozen blocks were cut into sections 10 μm thick
according to the methods described previously [16].
Serial sections 10 μm thick, 20 frontal sections in each
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knee, were prepared carefully in order to include the
severely degenerated area not covered by meniscus. Sec-
tions from each animal were used for histological,
immunohistochemical, and fluoroscopic analyses.
The sections were stained with H & E and safranin O
using standard methods. We assessed the severity of
knee OA using the modified Mankin criteria described
by Armstrong and colleagues [17], expressed as the OA
score. All sections were graded by three independent
observers blinded to the treatment group, and the med-
ian score was used for statistical analysis.
The tissue sections were also stained with a primary
polyclonal antibody, raised in rabbits against type II col-
lagen (dilution 1:200; COSMO BIO, Tokyo, Japan), for 1
hour at room temperature. After rinsing in PBS, the tis-
sue was incubated with biotinylated horse anti-rabbit
IgG secondary antibody for 30 minutes at room tem-
perature. Immunohistochemical staining was detected
with VECTA STAIN ABC Reagent (Vectastain Elite Kit;
Vector Laboratories, Burlingame, CA, USA), followed by
staining with 3,3-diaminobenzidine tetrahydrochloride
(Dojin Chemicals, Tokyo, Japan). In addition, to evaluate
the location of collagen type II relative to the cells, other
sections were incubated with the secondary antibody for
goat anti-rat Alexa Flour® 568-conjugated antibody
(1:250; Molecular Probes) for 1 hour at room tempera-
ture. These sections were counterstained with the
nuclear marker 4’,6-diamidino-2-phenylindole.
Cells labeled with CFDA-SE can be visualized by
fluorescence microscopy using standard fluorescein filter
sets. The approximate excitation and emission peaks of
this product after hydrolysis are 492 nm and 517 nm.
The labeled cells were quantified in 500 × 500 μm2
areas of tibial frontal section (original magnification,
×100).
Immunoblot analysis
Immunoblot analysis was carried out with 15% SDS-
PAGE. Total protein (80 μg/lane) extracted from the
cartilage was transferred onto polyvinylidene difluoride
membrane for 70 minutes using a semi-dry blot appara-
tus. The membrane was washed twice in PBS containing
0.05% Tween 20, blocked by 5% skimmed milk in PBS
for 1 hour at room temperature, and then incubated
with the collagen type I, collagen type II, or matrix
metalloproteinase-13 primary antibody (dilution 1:20;
COSMO BIO) overnight at 4°C, followed sequentially by
anti-mouse IgG antibody and avidin-biotinylated peroxi-
dase complex (for 30 minutes each). After triple washing
in 0.1 M PBS, the membrane was incubated in enhanced
chemiluminescence reagent for 1 minute, and then the
antibody binding was visualized using a FluorChem™
8000 System (Alpha Innotech Corporation, San Leandro,
CA, USA). The size of each band was normalized to b-
actin (lot number IMG-5142A, 1:1,000; Imgenex, San
Diego, CA, USA).
Statistical analysis
Data are expressed as the mean ± standard deviation.
Differences between groups were examined for statistical
significance using one-way analysis of variance followed
by the Bonferoni/Dunn post-hoc paired test for compari-
son between groups. P < 0.05 denoted the presence of a
significant difference between groups. The above tests
were conducted using the Statistical Package for Social
Sciences (version 11.0; SPSS Inc., Chicago, IL, USA).
Results
Assessment of xenogeneic transplantation of MSCs
Clinically, all guinea pigs tolerated the cell injection, and
there was no evidence of local inflammation, joint effu-
sion, or unloading of the joint resulting from the cell
treatment. Histologically, the frontal section of the
entire knee joint showed no evidence of synovial hyper-
plasia (Figure 1A, B, C). Fluorescence examination
showed labeled MSCs in the fibrillated cartilage at the
medial tibial plateau (Figure 1D’). A few labeled cells
were also detected in the synovial lining and medial
meniscus (Figure 1B’, C’), but no such cells were found
in the lateral region of the articular cartilage and menis-
cus (Figure 1E’).
Macroscopic findings
No India ink staining was observed in the lateral tibial
plateau of any specimen. In the PBS, HA, and PBS +
MSC groups, the surfaces of the articular cartilage over
the bare medial tibial plateau (not covered with the
meniscus) were rough and strongly stained at 5 weeks
post transplantation (Figure 2A, B, C). In the HA +
MSC group, the surface of the medial plateau was rela-
tively smooth and the staining intensity was weaker in
the same time interval (Figure 2D). The macroscopic
OA score was significantly lower in the HA + MSC
group than in the other groups (Figure 2E).
Histological findings
The PBS and PBS + MSC groups showed depletion of
chondrocytes (which extended to the transitional zone)
and matrix fibrillation (which extended from the transi-
tional zone to the radial zone) (Figure 3A, C). The safra-
nin-O-stained matrix was reduced in all treatment
groups with the exception of the HA + MSC group (Fig-
ure 3E, G). In the HA group, matrix fibrillation of the
articular surface did not extend to the radial zone (Fig-
ure 3B) and weak matrix staining and cell depletion
were observed (Figure 3F). The HA + MSC group
showed large numbers of chondrocytes with cluster for-
mations in the radial layer of the articular cartilage.
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Furthermore, the matrix around the cell clusters was
Figure 1 Xenogeneic transplantation of mesenchymal stem cells. (A to E) Photomicrographs showing frontal sections, 10 μm thick, of the
whole knee joint stained with safranin O. (B’ to E’) Fluorescent microscopy for in vivo tracing of injected mesenchymal stem cells (MSCs). Bar =
500 μm (A), 200 μm (B to E, B’ to E’).
Figure 2 Macroscopic findings. Macroscopic photographs (bird’s-eye view) of the articular surface of the tibial plateau 5 weeks after injection
of each reagent in Hartley strain guinea pigs, stained with India ink: (A) PBS group, (B) hyaluronic acid (HA) group, (C) PBS + mesenchymal
stem cell (MSC) group, (D) HA + MSC group. Arrowheads: stained lesions. (E) Macroscopic osteoarthritis (OA) scores in the same animal groups
evaluated 5 weeks after injection. Data are mean ± standard deviation of five guinea pigs in each group. *P < 0.05.
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strongly stained in safranin-O-stained sections at 5
weeks post transplantation (Figure 3D, H).
At 5 weeks post transplantation, significant differences
were noted between the OA scores of the PBS and HA
+ MSC groups, and between the scores of PBS + MSC
and HA + MSC groups (Figure 3I).
Immunohistochemical and immunoblot analyses
The immunostaining for type II collagen was stronger
and more extensive around the chondrocyte-like cells at
5 weeks in the HA + MSC group compared with the
other three treatment groups (Figure 4A). Similarly,
western blot analysis showed higher levels of type II col-
lagen in the HA + MSC group, relative to the PBS
group (Figure 4B). Weak bands of type I collagen were
observed in every group, and there were no significant
differences between the groups. The bands of matrix
metalloproteinase-13 were weaker in the HA + MSC
group, relative to the PBS and PBS + MSC groups (Fig-
ure 4B). Quantitative analysis confirmed these findings
(Figure 4C).
Fluorescent microscopic findings
A few CFDA-SE-labeled cells were found within the car-
tilage at 1 week post transplantation of the PBS + MSC
group (Figure 5A). The labeled cells gradually
disappeared from the cartilage at 3 and 5 weeks post
transplantation (Figure 5B, C). In contrast, the labeled
cells appeared both adhered to the surface and scattered
within the superficial and transitional layers of the carti-
lage at 1 week post transplantation in the HA + MSC
group (Figure 5D), but they were more frequent in the
transitional layer and showed a columnar arrangement
at 3 and 5 weeks (Figure 5E, F). The number of labeled
cells was higher in the HA + MSC group than in the
PBS + MSC group at all the time periods (Figure 5G).
These findings suggest that the CFDA-SE-labeled MSCs
in HA migrated into the OA cartilage and were asso-
ciated with the improved metachromasia and histology
OA score.
Double immunofluorescence stained sections were
evaluated for the distribution of residual chondrocytes,
labeled MSCs, and type II collagen in the OA cartilage
at 5 weeks post transplantation of HA + MSC injection.
Immunostaining for type II collagen was observed in the
matrix around residual chondrocytes in the radial layer
at 5 weeks (Figure 6B, C), in addition to pericellularly
and in the matrix between labeled MSCs in the transi-
tional layer (Figure 6B, D). These findings indicated
chondrogenic differentiation of the injected MSCs.
Figure 3 Histological findings. Photomicrographs showing serial frontal sections 10 μm thick stained with (A to D) H & E and (E to H)
safranin O. Bar = 100 μm in all sections. (I) Histological grade of knee osteoarthritis assessed by modified Mankin criteria 5 weeks after injection,
according to the treatment modality. Data are mean ± standard deviation of five guinea pigs in each group. *P < 0.05. HA, hyaluronic acid; MSC,
mesenchymal stem cell.
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Discussion
MSCs can be isolated from a variety of mature tissues,
and readily expand in culture without losing their multi-
lineage differentiation potential [4,18,19]. Moreover,
MSCs secrete a broad spectrum of bioactive molecules,
collectively known as trophic factors [20]. Previous
reports, however, have demonstrated that MSCs repre-
sent only 0.01 to 0.001% of the total nucleated cells
within isolated bone marrow aspirates [4] and that the
true identity of MSCs is often confused by various isola-
tion and in vitro culture methods [21]. In this regard,
preparation of large quantities of autologous MSCs for
therapeutic use from small experimental animals is
sometimes technologically difficult. Several groups
reported recently that MSCs produce molecules that are
directly involved in the regulation of the immune
Figure 4 Immunohistochemical and immunoblot analyses. Immunohistochemistry, western blotting, and quantification of type II collagen,
type I collagen, and matrix metalloproteinase (MMP)-13 expressions at week 5 after injection. (A) Immunohistochemical analysis for type II
collagen. Bar = 50 μm. (B) Western blot analysis of type II collagen, type I collagen, and MMP-13 (pooled samples in each group, n = 5). (C)
Quantitative analysis of the expressions of type II collagen, type I collagen, and MMP-13 relative to the intensity of b-actin. Data are mean ±
standard deviation of five guinea pigs in each group. *P < 0.05. HA, hyaluronic acid; MSC, mesenchymal stem cell.
Figure 5 Fluorescent microscopic findings. Fluorescent microscopy for in vivo tracing of injected mesenchymal stem cells (MSCs) at 1, 3, and
5 weeks. (A to C) PBS + MSC group. (D to F) Hyaluronic acid (HA) + MSC group. Bar = 50 μm. (G) Quantification of the carboxyfluorescein
diacetate succinimidyl ester (CFDA-SE)-labeled MSCs. Data are mean ± standard deviation of five guinea pigs in each group. *P < 0.05.
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response and have immunosuppressive properties, which
may be particularly important in allogeneic MSC trans-
plantation [22,23]. In addition, human MSCs evade
xenogeneic immune reactions and inhibit the inflamma-
tory response in collagen-induced arthritis in mice [24].
For these reasons, we used commercially available
human MSCs for xenogeneic MSC transplantation in
this study. In the present study, the guinea pigs tolerated
the cell injections well, and there was no evidence of
local inflammation. Frontal histological section of the
whole knee joint showed no evidence of synovial hyper-
plasia. Fluorescence microscopy also identified the pre-
sence of the labeled MSCs in the fibrillated cartilage at
the medial tibial plateau. A few labeled cells were also
detected in the synovial lining and medial meniscus.
In the present study, we evaluated the feasibility of
intra-articular injection of MSCs suspended in HA for
the treatment of knee OA. Our results at 5 weeks post
transplantation showed histologically confirmed partial
repair of the articular cartilage, compared with the three
other treatment groups. Immunoblot analysis also
showed increasing content of type II collagen and low
levels of matrix metalloproteinase-13 in the repaired
cartilage. In vivo tracing techniques using CFDA-SE
labeling and fluorescence microscopy demonstrated that
the intra-articularly injected MSCs in HA migrated
throughout the osteoarthritic cartilage. Double immuno-
fluorescence analysis also demonstrated strong, although
partial, immunostaining of type II collagen around both
residual chondrocytes and the injected MSCs after 5
weeks. These results imply intra-articular differentiation
of the injected MSCs into chondrocytes and their subse-
quent proliferation. While HA is known to influence
chondrocyte metabolism, the MSCs may produce
trophic factors that could also stimulate the residual
chondrocytes.
In our animal study, MSCs possibly produced trophic
factors for residual chondrocytes, in addition to differen-
tiating into chondrocytes in the presence of HA. While
the biochemical conditions necessary for stimulation of
chondrogenesis of MSCs in vitro have been defined [25],
little is known about the differentiation of MSCs into
chondrocytes and cartilage regeneration in vivo. Several
studies investigated chondrogenesis of grafted MSCs
within scaffolds in full-thickness cartilage defects in ani-
mal models [26,27]. The analyses in these studies
showed improved tissue filling and increased matrix
staining for type II collagen and proteoglycans 5 to 8
weeks after grafting. The studies’ results showed that
the transplanted cells secreted type II collagen and con-
tributed to articular cartilage repair. Although simple
injection of MSCs was not successful in the repair of
cartilage in the present study, MSCs suspended in HA
appeared to migrate and proliferate into the transitional
layer - and differentiation of these cells into chondro-
cytes was observed at week 5 after injection. For this
treatment group, there was partial repair of cartilage
degeneration, both macroscopically and microscopically.
The results thus suggest that HA is an important factor
in MSC transplantation into the articular cartilage.
There are several advantages for the use of the MSC
and HA mixture for intra-articular injection. HA exhi-
bits biological affinity for MSC binding via the trans-
membrane receptor CD44, which facilitates cell
migration through interaction with extracellular HA
[28]. HA also increases the chondrogenic activity of
Figure 6 Double immunofluorescence microscopic findings. Photomicrographs showing serial sections of articular cartilage 5 weeks after
injection in the hyaluronic acid (HA) + mesenchymal stem cell (MSC) group stained with (A) H & E and (B to D) double immunofluorescence
(red, type II collagen; green, MSCs; blue, 4’,6-diamidino-2-phenylindole (DAPI)). (B) corresponds to (A). (C) and (D) are magnified views of the
boxes marked in (B). Bar = 100 μm (A, B), 50 μm (C, D).
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MSCs [29]. Another study demonstrated that HA coats
the surface of the articular cartilage and also locates
among the collagen fibrils and sulfated proteoglycans
within the cartilage [30]. Furthermore, in vitro experi-
ments indicated that HA alone enhanced the rate of
synovial cell migration, and that HA increased chondro-
cyte migration in the presence of basic fibroblast growth
factor [31]. Considered together, our findings and the
results of the above studies emphasize the importance
of HA in facilitating the migration, adherence, and dif-
ferentiation of MSCs onto the OA cartilage.
Previous studies used the MSC-HA combination for
cartilage repair in surgically induced OA [9,10], but not
for spontaneous OA as was carried out in the present
study using the Hartley strain guinea pigs. We com-
pared the difference between disease progression of
Hartley guinea pigs knees, with and without transection
of the anterior cruciate ligament [32]. Their results
showed accelerated cartilage degeneration and higher
levels of matrix metalloproteinase-13 and IL-1b, which
is a key mediator for OA progression, in the anterior
cruciate ligament transection model. These results indi-
cated that the progression of OA may differ between
surgically induced and spontaneous OA. In this regard,
this animal model of spontaneous OA is considered
more suitable for the evaluation of disease-modifying
OA treatments.
Our study has certain limitations that should be con-
sidered when interpreting the results of the experiments.
These include the use of nonphysiologic conditions for
xenogeneic MSC transplantation, possible deterioration
of the repaired cartilage after injection, a lack of ultra-
structural analysis such as morphological evaluation by
electron microscopy to clarify the in vivo chondrogen-
esis of MSCs in OA cartilage after the injection, a lack
of re-examination of optimum timing of injection during
OA progression, lack of a MSC population isolated from
various types of adult mesenchymal tissues and various
issues related to the transplantation of autologous or
xenogeneic derived stem cells, and the use of HA only
instead of including another compound with molecular
weight similar to HA. Further studies are needed that
include the above points. Should these issues be
resolved satisfactorily, then intra-articular injection of
MSCs suspended in HA could be a potentially useful
therapeutic intervention for the treatment of sponta-
neous knee OA.
Conclusion
The results of the present study suggest that intra-
articular injection of MSCs with HA is a potentially
beneficial therapy for OA. HA exerts cell-binding and
cytotactic effects, thus enhancing the migration and pro-
liferation of MSCs. Although further examination of the
long-term effects is necessary, this scaffold-free, mini-
mally invasive treatment seems to retard the progression
of spontaneous OA and stimulates the regeneration of
articular cartilage.
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